Foundayo vs Zepbound for Weight Management

Foundayo and Zepbound are two weight-management drugs from Eli Lilly, both approved by the U.S. Food and Drug Administration (FDA). Foundayo is a daily glucagon-like peptide-1 (GLP-1) receptor agonist pill. Zepbound is a weekly injection that activates glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors.^1-3 ATTAIN-1 reported an average 11.2% weight reduction at week 72 with the highest orforglipron dose studied, and SURMOUNT-1 reported a 20.9% reduction at week 72 with the highest tirzepatide dose studied.^4,5 No head-to-head trial has compared them.

Foundayo vs Zepbound at a Glance

Foundayo and Zepbound come from the same manufacturer, but their active ingredients, receptor targets, and delivery methods differ. Their labels also cover different indications.

	Foundayo	Zepbound
Active ingredient	Orforglipron	Tirzepatide
Receptor target	GLP-1 receptor	GIP and GLP-1 receptors
Form and schedule	Small-molecule tablet taken once daily	Subcutaneous injection taken once weekly
Manufacturer	Eli Lilly and Company	Eli Lilly and Company
Label indications	Long-term weight reduction and maintenance in adults with obesity or overweight with at least one weight-related condition	Long-term weight reduction and maintenance in adults with obesity or overweight with at least one weight-related condition. Also approved for moderate to severe obstructive sleep apnea in adults with obesity
Main weight trial and length	ATTAIN-1, 72 weeks in adults with obesity without diabetes	SURMOUNT-1, 72 weeks in adults without diabetes
Average weight change for the highest dose studied (vs placebo)	11.2% reduction vs 2.1% with placebo	20.9% reduction vs 3.1% with placebo
Most common side effects	Gastrointestinal effects, including nausea, constipation, diarrhea, and vomiting	Gastrointestinal effects, including nausea, diarrhea, vomiting, and constipation. Injection-site reactions also occurred
Stopped for adverse reactions in the label safety pool	8% vs 3% with placebo	4.8% to 6.7% across the studied strengths vs 3.4% with placebo
Price (read September 15, 2026)	Lilly listed a regular self-pay range of $149 to $349 for a one-month supply, depending on strength.6	See the GLP-1 cost guide for current Zepbound prices

The percentages in the table come from separate trials with different participants and protocols.^4,5

Repeated labs and measurements show how your body responds over time, which gives your physician a basis for adjustment.

Different Receptors and Different Delivery

Foundayo activates the GLP-1 receptor, which is involved in appetite and caloric intake.¹ Orforglipron is a small-molecule, nonpeptide drug designed for oral use.⁴

Zepbound activates both GIP and GLP-1 receptors.² Tirzepatide is delivered as a weekly subcutaneous injection. The added GIP activity is a genuine mechanism difference, although receptor count alone cannot predict your personal response.

The Foundayo label specifies once-daily oral administration with or without food. It also specifies that the tablet remains whole.¹ Your prescriber or pharmacist explains how those conditions fit around your other medications.

Foundayo delays gastric emptying and may affect the absorption of other oral medicines.¹ If you take prescription tablets, your physician will review that medication list before choosing Foundayo. Zepbound avoids a daily tablet but requires a weekly injection.

Delivery preference can affect whether you stay consistent with treatment. You may prefer a pill because you want to avoid injections. You may prefer a weekly schedule because taking a daily medication would be harder to maintain.

A daily pill or weekly injection can become a quick fix when the broader drivers of weight gain are left unexamined. Our physician-led weight evaluation can examine insulin, leptin, ghrelin, cortisol, sex hormones, thyroid function, sleep, eating habits, activity, and stress. A panel of 55+ biomarkers gives the physician a baseline for a personalized plan.

If oral treatment is your main priority, the Foundayo vs Wegovy pill comparison addresses two pill options. The tirzepatide vs semaglutide comparison covers a separate clinical decision involving semaglutide.

Reading ATTAIN-1 and SURMOUNT-1

ATTAIN-1 tested once-daily orforglipron for 72 weeks in 3,127 adults with obesity and without diabetes. Participants also received guidance on diet and physical activity.⁴

Average weight reduction at week 72 was 7.5% with the lowest dose studied, 8.4% with the middle dose, and 11.2% with the highest dose. The placebo group lost an average of 2.1%.⁴ The dose strengths studied in ATTAIN-1 do not map directly to the marketed Foundayo tablet strengths.

SURMOUNT-1 tested once-weekly tirzepatide for 72 weeks in 2,539 adults without diabetes. Participants had obesity or overweight with at least one weight-related complication.⁵

Average weight reduction was 15.0% with the lowest dose studied, 19.5% with the middle dose, and 20.9% with the highest dose. The placebo group lost an average of 3.1%.⁵

Those figures do not establish that Zepbound will cause nearly twice as much weight loss for you. ATTAIN-1 and SURMOUNT-1 enrolled separate groups and used different protocols. Neither trial assigned participants to both drugs under the same conditions.

Trial averages also contain a range of individual responses. Some participants lost more than the average, while others lost less. Your response, side effects, medical history, and ability to follow the treatment schedule give your physician more useful information than a cross-trial ranking.

A comparison becomes more informative after treatment begins. Your physician can track body weight, waist measurements, metabolic markers, side effects, and adherence over time. A single measurement does not establish a trend. Repeated measurements let your physician see whether weight change and metabolic markers are moving together. That pattern can support a dose adjustment or a discussion about another medication.

Weight Management and Sleep Apnea Indications

Both labels cover long-term weight reduction and weight maintenance in adults with obesity. They also cover adults with overweight who have at least one weight-related condition.^1,2

Zepbound has an additional indication. Its label includes treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.² Foundayo does not carry that indication.

OSA affects breathing during sleep. If you have diagnosed moderate to severe OSA and obesity, the Zepbound indication may influence your physician’s choice. It gives the physician a labeled reason to consider tirzepatide for both weight management and OSA treatment.

The extra indication does not make Zepbound the default choice for everyone. If OSA is absent, your physician will put more weight on route preference, medication interactions, previous treatment response, and tolerability. Your full health picture sets the priority.

Tolerability Across the Two Label Safety Pools

Gastrointestinal symptoms were the most common adverse reactions in both label safety pools. Rates from separate drug trials cannot be compared directly because the participants and study methods differed.^1,2

The Foundayo safety pool included 3,155 adults treated for up to 72 weeks. Across the maintenance strengths studied, nausea occurred in 26% to 35%, constipation in 20% to 27%, diarrhea in 21% to 25%, and vomiting in 13% to 24%.¹ Eight percent of Foundayo-treated participants permanently stopped treatment because of adverse reactions, compared with 3% receiving placebo.¹

The Zepbound safety pool included 2,519 adults treated for up to 72 weeks. Nausea occurred in 25% to 29%, diarrhea in 19% to 23%, vomiting in 8% to 13%, and constipation in 11% to 17%. Injection-site reactions occurred in 6% to 8%.² Permanent discontinuation because of adverse reactions ranged from 4.8% to 6.7%, compared with 3.4% for placebo.²

Both treatments use gradual escalation. The Foundayo label states that escalation is used to reduce gastrointestinal reactions. In SURMOUNT-1, gastrointestinal events occurred mainly during dose escalation and were usually mild to moderate.^1,5 Your prescriber sets the escalation schedule and adjusts the plan according to your response.

If you are already taking one of these drugs, your own tolerance has more relevance than a percentage from the other label. Persistent nausea, vomiting, constipation, or diarrhea should be reviewed by your prescriber. A pill preference carries little value if the medication is difficult for you to tolerate.

Body composition also deserves attention during medical weight management. The GLP-1 muscle loss guide covers protecting lean mass during GLP-1 treatment.

The Physician Decision Between a Pill and an Injection

A physician chooses between Foundayo and Zepbound by combining the label indications with your medical history, current medications, preferences, and previous response. There is no universal winner.

The label schedule is only one part of a personalized plan. Labs and a physician consultation repeat every 3 to 4 months so the plan can change with your measured response.

Foundayo may fit you if avoiding injections is a high priority and a daily tablet works with your routine. Your physician will also review your oral medications because Foundayo can affect their absorption.¹

Zepbound may receive more consideration if you have obesity and diagnosed moderate to severe OSA. Its weekly schedule may also fit you better if daily medication adherence is a concern.²

If you already use Zepbound, your response so far becomes part of the decision. Weight change, gastrointestinal effects, injection tolerance, and your ability to maintain the weekly schedule all give your physician concrete information. A switch based only on the ATTAIN-1 and SURMOUNT-1 averages would ignore your own treatment record.

The Foundayo label does not recommend using it at the same time as another GLP-1 receptor agonist.¹ Any transition from Zepbound to Foundayo therefore belongs with your prescriber. The labels do not provide a self-directed switching schedule between these two drugs.

Foundayo is contraindicated under its label if you have a personal or family history of medullary thyroid carcinoma (MTC), if you have multiple endocrine neoplasia syndrome type 2 (MEN 2), or if you have a serious hypersensitivity to orforglipron.¹ Zepbound carries a boxed warning based on thyroid C-cell tumors in rats, with the human relevance remaining unknown.² Your physician will review your personal and family history before prescribing either medication.

For a broader view of treatment selection, monitoring, and metabolic health, see the GLP-1 guide for men.

The Opt Take on Foundayo vs Zepbound

Before any GLP-1 prescription through Opt Health, a physician reads your labs against your health history and goals. The medication and delivery form then follow your numbers, tolerance, and preferences.

The drug choice is one part of a physician-built weight-management plan. Your physician also needs to interpret your labs against your sleep, medications, hormones, metabolic health, side effects, and daily routine.

Opt Health begins with a panel of 55+ biomarkers and a one-to-one physician consultation. The physician builds your plan from that baseline, then repeats labs and consultations every three to four months. Treatment can change when your numbers, symptoms, or goals change.

That ongoing loop is especially useful when two medications have separate trial results and no direct comparison. Your initial choice does not have to become a permanent assumption. Your response provides new data, and your physician can adjust the plan around it.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

Self-pay prices and offer terms can change without notice. Verify current figures on the Lilly Foundayo coverage page before relying on them.

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.